Trading Review for Adventrx Pharmaceuticals Inc. issued by Beacon Equity
The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
(EMAILWIRE.COM, October 23, 2009 ) DALLAS, Texas - BeaconEquity.com announces an investment report featuring biopharmaceutical company Adventrx Pharmaceuticals Inc. (AMEX: ANX).
The investment report on Adventrx Pharmaceuticals Inc. (AMEX: ANX) should be of particular interest to other pharmaceutical companies: GlaxoSmithKline plc (NYSE: GSK), Roche Holdings Ltd. (OTCPK: RHHBY) and Sanofi-Aventis (NYSE: SNY).
It is available at: http://www.beaconequity.com/i/ANX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Adventrx Pharmaceuticals Inc. (ANX) engages in the development of proprietary drug candidates for the treatment of cancer. The Company intends to in-license and commercialize two late-stage drug therapy candidates, ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion). Both of these product candidates are reformulation of presently approved drug therapies.
Message Board Search for ANX: http://www.boardcentral.com/boards/ANX
In the report, the analyst notes:
“Like most enterprises seeking funding during the largest credit crunch since the 1930s, the Company has transformed to a highly outsourced business model. Most of the development activities are contracted, leaving a minimal number of full-time employees on payroll, as well as adding flexibility to the Company's operations.
“The Company has undergone four financings since June (in June, July and August), of which are expected to get the Company through an important milestone of a Food and Drug Administration (FDA) decision regarding ANX-530 expected sometime in 2010. Management believes the period between the latest financing of early October and the scheduled FDA decision in 2010 lowers the credit risk to the Company and investors.”
To read the entire report visit: http://www.beaconequity.com/i/ANX
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
The investment report on Adventrx Pharmaceuticals Inc. (AMEX: ANX) should be of particular interest to other pharmaceutical companies: GlaxoSmithKline plc (NYSE: GSK), Roche Holdings Ltd. (OTCPK: RHHBY) and Sanofi-Aventis (NYSE: SNY).
It is available at: http://www.beaconequity.com/i/ANX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Adventrx Pharmaceuticals Inc. (ANX) engages in the development of proprietary drug candidates for the treatment of cancer. The Company intends to in-license and commercialize two late-stage drug therapy candidates, ANX-530 (vinorelbine emulsion) and ANX-514 (docetaxel emulsion). Both of these product candidates are reformulation of presently approved drug therapies.
Message Board Search for ANX: http://www.boardcentral.com/boards/ANX
In the report, the analyst notes:
“Like most enterprises seeking funding during the largest credit crunch since the 1930s, the Company has transformed to a highly outsourced business model. Most of the development activities are contracted, leaving a minimal number of full-time employees on payroll, as well as adding flexibility to the Company's operations.
“The Company has undergone four financings since June (in June, July and August), of which are expected to get the Company through an important milestone of a Food and Drug Administration (FDA) decision regarding ANX-530 expected sometime in 2010. Management believes the period between the latest financing of early October and the scheduled FDA decision in 2010 lowers the credit risk to the Company and investors.”
To read the entire report visit: http://www.beaconequity.com/i/ANX
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Contact Information:
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Beacon Equity
Jeff Bishop
Tel: (469)-252-3505
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |